Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$782.51
-$21.82 (-2.7%)
Closing Price on November 14, 2024
REGN Articles
One area is dirt cheap now, and in some cases pays dividends and has big growth prospects, and that is the large cap biotechs.
Published:
Last Updated:
2016's 50 most innovative companies are topped by Apple, Google and Tesla. Among the companies making the biggest moves were Netflix and Facebook, and new entrants on the list included Uber and...
Published:
Last Updated:
Thethe top analyst upgrades, downgrades and initiations seen on Monday include AK Steel, JC Penney, Hasbro, Petrobras, Travelers, Agilent Technologies and Regeneron.
Published:
Last Updated:
Five companies with stocks rated Buy at Merrill Lynch and that do all of their business in the United States, which is critical, given the stronger dollar.
Published:
Last Updated:
Chasing stocks in an overbought market is dangerous. With that in mind, overbought markets can go higher. These stocks hold the proverbial big risk, big reward handle.
Published:
Last Updated:
2017 could be different for the health care sector. It is very possible that this new administration could lead to more positive trials, FDA approvals, and mergers and acquisitions.
Published:
Last Updated:
Companies receiving analyst upgrades, downgrades, initiations or other key notes on Tuesday morning include Alcoa, Arch Coal, Baidu, Ciena, JD.com and Vale.
Published:
Last Updated:
Here are, the 11 top stock picks from the analysts at Merrill Lynch for 2017. Most look well-suited for growth portfolios that have a degree of risk tolerance.
Published:
Last Updated:
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
Published:
Last Updated:
Regeneron Pharmaceuticals reported mixed third-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development.
Published:
Last Updated:
An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four top biotech companies may be a solid play now.
Published:
Last Updated:
Stocks overall were fractionally higher early on Monday, August 29, 2016. That makes the big percentages gainers and losers and the companies with big headline news stand out even more.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday morning include FireEye, Occidental Petroleum, SeaWorld, Teva Pharmaceutical, Windstream and Zynga.
Published:
Last Updated:
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
Published:
Last Updated: